Association of C1QB gene polymorphism with schizophrenia in Armenian population

Roksana Zakharyan1,2, Aren Khoyetsyan1, Arsen Arakelyan1, Anna Boyajyan1, Anaida Gevorgyan3, Anna Stahelova2, Frantisek Mrazek2 and Martin Petrek2

Abstract

Background: Schizophrenia is a complex, multifactorial psychiatric disorder. Our previous findings indicated that altered functional activity of the complement system, a major mediator of the immune response, is implicated in the pathogenesis of schizophrenia. In order to explore whether these alterations are genetically determined or not, in the present study we evaluated the possible association of complement C1Q component gene variants with susceptibility to schizophrenia in Armenian population, focusing on four frequent single nucleotide polymorphisms (SNPs) of C1QA and C1QB genes.

Methods: In the present study four SNPs of the complement C1Q component genes (C1QA: rs292001, C1QB rs291982, rs631090, rs913243) were investigated in schizophrenia-affected and healthy subjects. Unrelated Caucasian individuals of Armenian nationality, 225 schizophrenic patients and the same number of age- and sex-matched healthy subjects, were genotyped. Genotyping was performed using polymerase chain reaction with sequence-specific primers (PCR-SSP) and quantitative real-time (qRT) PCR methods.

Results: While there was no association between C1QA rs292001, C1QB rs913243 and rs631090 genetic variants and schizophrenia, the C1QB rs291982*G minor allele was significantly overrepresented in schizophrenic patients (G allele frequency 58%) when compared to healthy subjects (46%, OR = 1.64, pcorr = 0.0008). Importantly, the susceptibility for schizophrenia was particularly associated with C1QB rs291982 GG genotype (OR = 2.5, pcorrected = 9.6E-5).

Conclusions: The results obtained suggest that C1QB gene may be considered as a relevant candidate gene for susceptibility to schizophrenia, and its rs291982*G minor allele might represent a risk factor for schizophrenia at least in Armenian population. Replication in other centers/populations is necessary to verify this conclusion.

Background

Schizophrenia is a complex and severe psychiatric disorder manifested by a disruption in cognition and emotion along with negative (avolition, alogia, apathy, poor social functioning) and positive (hallucinations, delusions) symptoms [1,2]. According to the neurodevelopmental theory, the etiology of schizophrenia may involve pathological processes in the brain induced by environmental factors during the early stage of brain formation [reviewed in [3]]. These processes result in genetic abnormalities leading to dysfunction of specific neural network, which might contribute to the premorbid signs for the later developed schizophrenia [3]. Evidence from epidemiological and genetic studies suggest a high degree of heritability of schizophrenia and point to a number of potential candidate genes that may be perturbed early in development leading ultimately to the development of psychotic symptoms [reviewed in [3-5]]. However, the molecular etiopathomechanisms of this disorder are still unclear.

Our recent studies indicate the crucial role of the immune system in schizophrenia and provide evidence on the alterations in the major mediator of the immune response, the complement system, in pathogenesis of this disorder [6-13]. In particular, increased functional activities of the complement classical pathway and C1Q protein, the initiator of the complement classical pathway, which might contribute to the premorbid signs for the later developed schizophrenia [3]. Evidence from epidemiological and genetic studies suggest a high degree of heritability of schizophrenia and point to a number of potential candidate genes that may be perturbed early in development leading ultimately to the development of psychotic symptoms [reviewed in [3-5]]. However, the molecular etiopathomechanisms of this disorder are still unclear.

© 2011 Zakharyan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
cascade, in schizophrenia-affected subjects has been found [8,10]. These findings are of special interest accounting for a positive linkage of schizophrenia with chromosome 1p36 loci located nearby CIQA and CIQB genes (1p36.12) [14,15]. Notably, for other components of the complement association of genetic polymorphisms with schizophrenia has been demonstrated [11,16]. In addition association of genetic diversity of HLA-III encoding complement proteins with susceptibility to schizophrenia has been also shown [17]. However, no data regarding association of C1Q encoding genes (CIQA and CIQB) polymorphisms to schizophrenia have been published yet. To explore whether the alterations in C1q activity in schizophrenia are genetically determined or not, in the present study we evaluated the possible association of complement C1Q component gene variants with susceptibility to schizophrenia in Armenian population, focusing on four CIQA and CIQB intronic single nucleotide polymorphisms (SNPs); two tagged SNPs were selected by Martens et al. [2009] using HapMap project [18] and the other two were chosen according to their frequent appearance in European Caucasoid population (minor allele frequency > 10%) and their potential functional effect (gain/loss of binding site for transcription factors) [19-22]. To our knowledge, this is the first study investigating association of the CIQA and CIQB genetic variants with schizophrenia. This study might contribute to understanding the molecular pathomechanisms responsible for generation and development of schizophrenia.

Methods

Study population

In total, 450 unrelated Caucasian individuals of Armenian nationality living in Armenia (225 schizophrenic patients and 225 healthy subjects) were enrolled in this study. All patients (female/male: 71/154, mean age ± SD: 44.2 ± 9.8 years, age at the first-onset of illness: 26.4 ± 8.3 years, duration of illness: 19.5 ± 7.2 years, patients with/without family history of psychiatric disorders: 94/131) were diagnosed as paranoid schizophrenics (ICD-10 code: F20.0, DSM-IV-TR code: 295.30) by two independent experienced psychiatrists [1,2]. The affected subjects were recruited from the clinics of the Psychiatric Medical Center of the Ministry of Health of the Republic of Armenia (MH RA). Age- and sex-matched healthy volunteers (female/male: 71/154, mean age ± SD: 42.6 ± 9.2 years) were recruited among the staff and blood donors of the Erebouni Medical Center MH RA. Exclusion criteria for healthy subjects included psychiatric illness during lifetime, any serious neurological or endocrine disorder, any medical condition or treatment known to affect the brain, or meeting DSM-IV criteria for mental retardation as determined from the non-patient version of the Structured Clinical Interview for DSM-IV-TR Axis I Disorders [23]. Exclusion criteria for all study participants included any serious medical disorder. All subjects gave their informed consents to participate in the study, which was approved by the Ethical Committee of the Institute of Molecular Biology of the National Academy of Sciences RA.

Genomic DNA extraction

Genomic DNA samples were isolated from fresh blood according to the standard phenol-chloroform method [24] and stored at -30°C until further use.

Genotyping analysis

All DNA samples were genotyped for four SNPs, namely CIQA rs292001, CIQB rs913243, rs291982 and rs631090. CIQA rs292001, CIQB rs291982 and rs631090 SNPs were genotyped by polymerase chain reaction with sequence-specific primers (PCR-SSP) under the conditions described elsewhere [25]. All primers for PCR-SSP were designed using the genomic sequences in the GenBank (http://www.ncbi.nlm.nih.gov, GenBank ID:712, 713). The primer sequences for three mentioned SNPs were as follows: 1) rs292001: allele G, reverse 5’GAT GCC CGG ATG CAA ATT AC, allele A, reverse 5’GAT GCC CGG ATG CAA ATT AT, constant forward 5’AGG CTT CAG AGA CTC ACA TTC; 2) rs291982: allele T, reverse 5’ACC TTT GCC CAG ATC CAA ATT, allele G, reverse 5’ACC TTT GCC CAG ATC CAA ATG, constant forward 5’AGC CAC AAG TCC CAA TGA; 3) rs631090: allele T, forward 5’CAC GGA TCT CCT ACC ATT AAA T, allele C, forward 5’CACC GGA TCT CCT ACC ATT AAA C, constant reverse 5’CAT CTG TGA AAT GGG GAT CAA GA. The presence/absence of allele-specific amplicons was visualized by 2% agarose gel stained with ethidium bromide fluorescence in reference to a molecular weight marker. Genotypes for CIQB rs913243G/T SNP were determined using TaqMan SNP genotyping assay (Applied Biosystems, Assay ID C_3176751_10) according to the manufacturer’s instruction. Randomly selected samples (n = 45; 10% of the total number) were amplified twice to check for confidence of genotyping, and in each case complete concordance was obtained.

Statistical analysis

The distributions of genotypes for all investigated SNPs were checked for correspondence to the Hardy-Weinberg (H-W) equilibrium. In order to find potential relevance of the selected SNPs to schizophrenia, their allele and genotype frequencies (carriage rates) in patients and control subjects were compared. The calculations of allele and genotype frequencies were based on the observed number of genotypes. Estimated proportion of
haplotypes and linkage disequilibrium (LD) between investigated loci were calculated using SNP analyzer software [26]. Maximum-likelihood (ML) haplotype frequencies in patients and control subjects were estimated using an expectation-maximization (EM) algorithm [27]. The significance of differences between allele and genotype frequencies in both groups was determined using Pearson’s Chi-square test. The odds ratio (OR), 95% confidence interval (CI), and Pearson’s p-value were calculated. Statistical power of the present study was calculated according to the protocol described elsewhere [28]. P-values were adjusted by Bonferroni multiple correction approach [29], and those less than 0.05 were considered statistically significant.

Results

The genotype distributions of studied SNPs in both patients and controls complied with H-W equilibrium (p > 0.05). Statistical power of the present study, indicating the difference in the C1QB rs291982*G allele frequency between the patients and healthy controls for the odds ratio (OR) 2.5 reached 100%, for OR = 2.0 99.9%, while for OR = 1.2 was 38.8%.

The frequencies of all studied genetic variants in the groups of schizophrenic patients and control subjects are shown in Table 1. C1QA rs292001 and C1QB rs913243 polymorphisms were almost equally represented in both groups (p > 0.05). By contrast, significant differences in the C1QB rs631090*C (22% vs 17%, OR = 1.4, 95%CI: 1.01-1.95, p_{nominal} = 0.044) and rs291982*G (58% vs 46%, OR = 1.64, 95%CI: 1.26-2.13, p_{nominal} = 0.0002) minor allele frequencies between schizophrenic patients and healthy subjects were found. After Bonferroni correction for the number of tested loci (n = 4), C1QB rs291982*G minor allele remained more frequent at significant level in schizophrenics compared to controls (p_{corrected} = 0.0008). The overall distribution of C1QB rs291982 genotypes differed between the patients and controls (p_{corrected} = 0.0004, 2 degrees of freedom, d.f.) due to the overrepresentation of rs291982 GG homozygotes among schizophrenics (36% vs 19%, p_{nominal} = 2.4E-5, p_{corrected} = 9.6E-5, 1 d.f., OR = 2.5, 95%CI: 1.62-3.85). Further, the rs291982 GG genotype was associated with increased risk for schizophrenia when compared to both TG (p_{corrected} = 0.0004) and TT (p_{corrected} = 0.0016) genotypes. In contrast, the susceptibility to schizophrenia was almost equal in rs291982 TG and TT genotypes (p_{nominal} = 0.82). These results suggest that the C1QB rs291982*G minor allele might be considered as a risk factor for schizophrenia in a homozygous status (GG genotype, recessive model), at least in Armenian population.

Haplotype analysis was performed to confirm the observed association and to estimate the ML C1QA/C1QB (rs292001/rs913243/rs291982/rs631090) haplotype frequencies. In total, 16 haplotypes in each group

### Table 1 Distribution of C1QA/C1QB genotypes and carriage of minor alleles in patients with schizophrenia (SCZ) and healthy subjects (Controls).

| SNP ID   | Genotype 1 | Genotype 2 | Genotype 3 | Allele 1 | Allele 2 | Carriage |
|----------|------------|------------|------------|----------|----------|----------|
| rs292001 | GG         | GA         | AA         | G        | A        | A        |
| SCZ      | 76 (0.34)  | 112 (0.50) | 37 (0.16)  | 264 (0.59)| 186 (0.41)| 149 (0.66)|
| Controls | 59 (0.26)  | 119 (0.53) | 47 (0.21)  | 237 (0.53)| 213 (0.47)| 166 (0.74)|
| p        | 0.170a     | 0.070b     | 0.080c     |
| rs913243 | GG         | GT         | TT         | G        | T        | T        |
| SCZ      | 68 (0.30)  | 123 (0.55) | 34 (0.15)  | 259 (0.58)| 191 (0.42)| 157 (0.70)|
| Controls | 64 (0.28)  | 124 (0.56) | 37 (0.16)  | 254 (0.56)| 196 (0.44)| 161 (0.72)|
| p        | 0.882a     | 0.638b     | 0.679c     |
| rs291982 | TT         | TG         | GG         | T        | G        | G        |
| SCZ      | 46 (0.20)  | 97 (0.44)  | 82 (0.36)  | 189 (0.42)| 261 (0.58)| 179 (0.80)|
| Controls | 61 (0.27)  | 122 (0.54) | 42 (0.19)  | 244 (0.54)| 206 (0.46)| 164 (0.73)|
| p        | 0.0001a    | 0.0002b    | 0.007c     |
| rs631090 | TT         | TC         | CC         | T        | C        | C        |
| SCZ      | 153 (0.68) | 79 (0.35)  | 11 (0.05)  | 349 (0.78)| 101 (0.22)| 90 (0.40)|
| Controls | 155 (0.68) | 67 (0.30)  | 5 (0.02)   | 373 (0.83)| 77 (0.17) | 72 (0.32)|
| p        | 0.113a     | 0.044b     | 0.077c     |

The data are presented as absolute numbers with proportions (%) in parentheses.

- a nominal p-values for comparison of overall distribution of C1QA/C1QB genotypes between SCZ and Controls (2 degrees of freedom);
- b nominal p-values for comparison of Allele 2 proportion between SCZ and Controls;
- c nominal p-values for comparison of Allele 2 carriage between SCZ and Controls.
of study subjects were estimated. Interestingly, haplotype comparison between patients and healthy controls revealed five haplotypes with nominally significant differences between schizophrenic patients and controls, namely, A-T-T-T (haplotype frequencies in patients vs controls: 13% vs 19%, OR = 0.57, 95%CI: 0.40-0.81, \( p_{\text{nominal}} = 0.02, p_{\text{corrected}} = 0.32 \), A-G-T-T (4% vs 11%, OR = 0.41, 95%CI: 0.23-0.74, \( p_{\text{nominal}} = 0.002, p_{\text{corrected}} = 0.03 \)), A-G-G-T (8% vs 4%, OR = 2.02, 95%CI: 1.13-3.63, \( p_{\text{nominal}} = 0.015, p_{\text{corrected}} = 0.24 \)), G-G-G-C (8% vs 2%, OR = 1.99, 95%CI: 1.03-3.84, \( p_{\text{nominal}} = 0.049, p_{\text{corrected}} = 0.78 \)), and A-T-G-C (1% vs 0.6%, OR = 4.43, 95% CI: 1.25-15.66, \( p_{\text{nominal}} = 0.009, p_{\text{corrected}} = 0.14 \)), only one of which (A-G-T-T) remained significant after the correction for the number of haplotypes. The difference in A-G-T-T haplotype between patients and controls suggested that the \( C1QB \) rs291982 major T allele is less frequent in patients with schizophrenia than in controls. Importantly, these data are in complete concordance with major allele frequencies in both groups. The haplotype analysis, therefore, confirmed detected association of the \( C1QB \) rs291982 variant with schizophrenia.

In both patients and controls pair-wise linkage disequilibrium (LD) between the investigated \( C1QB \) rs913243, rs291982, and rs631090 SNPs was determined. LD blocks of \( C1QB \) gene SNPs and values of absolute \( D' \) as well as \( r^2 \) for both groups are presented in Figure 1.

**Discussion**

In this study the possible association of several polymorphisms of the complement C1Q component gene with susceptibility to schizophrenia was evaluated. No association of \( C1QA \) rs292001, \( C1QB \) rs913243 and rs631090 variants with disease was observed, whereas positive association of \( C1QB \) rs291982*G variant and namely GG genotype with schizophrenia was found. The results suggest that the \( C1QB \) rs291982*G minor allele might be in a homozygous status a risk factor for schizophrenia at least in Armenian population. Therefore, \( C1QB \) gene may be considered as a relevant candidate gene for susceptibility to schizophrenia.

The functionality of \( C1QA \) rs292001 and \( C1QB \) rs631090 has been previously shown in lupus erythematosus [18]. Nevertheless, our study revealed no association of these two functional variants with schizophrenia. At present, there are no published data on functionality of the \( C1QB \) rs291982 and rs913243 polymorphisms. In order to explore possible functional role of these genetic variants, we use the web server ALGGEN, a convenient tool for identification of the functional effects of SNPs [30]. Analysis showed that both \( C1QB \) rs291982 and rs913243 SNPs were found to be intronic enhancers. Thus, the \( C1QB \) rs291982 minor G allele contains binding sites for transcription factors forkhead box P3 (FOXP3, also known as hepocyte nuclear factor 3 (HNF3), forkhead homologue 2 or HFH-2), progesterone receptor isofrom A (PRA) and B (PRB), absent in the T major allele. Further, the rs913243 G/T polymorphism of the \( C1QB \) gene leads to loss of binding sites of glucocorticoid receptor-alpha and retinoid × receptor-alpha transcription factors. Whereas these types of functional effects have low phenotypic risk [31], the results of our analysis might indicate the functionality of the \( C1QB \) rs291982 and rs913243 SNPs as enhancers, transcription-stimulating DNA regulatory elements [32]. Importantly, these transcription factors might have an indirect impact on the immune system [19-22], therefore, might contribute to the etiology of schizophrenia taken into account immune system alterations in this disease [6-13].

The association between the \( C1QB \) rs291982*G genetic variant and schizophrenia obtained in our study may suggest the etiological significance of \( C1QB \) gene in schizophrenia in Armenian population. Furthermore, this finding may reflect implication of neurodegenerative component in schizophrenia [3]. Thus, Grewal et al (1999) demonstrated overexpression of \( C1QB \) in the areas undergoing neurodegeneration [33]. In addition, recent studies showing alterations in expression of \( C1QB \) gene in hippocampus and cerebral cortex in the animal models of Alzheimer’s disease [33,34], having some clinical features shared with schizophrenia such as neuron loss and cognitive impairment [1].

There may be another possible explanation of the association observed in our study in the light of the vascular-inflammatory theory of schizophrenia [35].
theory is based on observations that inflammatory vascular disease of the brain leads to psychosis and exhibits a fluctuating course as seen in schizophrenia, and that disturbances of central nervous system blood flow have repeatedly been observed in people with schizophrenia [35]. Interestingly, it has been demonstrated that the human cerebrovascular smooth muscle cells (HCSMC) isolated from cortical vessels derived from postmortem brains can express mRNAs for complement C1QB gene. As HCSMC are closely associated with amyloid beta deposits in vessels in the brain, their production of complement proteins could amplify the proinflammatory effects of amyloid in the perivascular environment, further compromising brain vascular integrity [36].

Also, the observed differences in the C1QB gene LD blocks between the patients with schizophrenia and control subjects may suggest that C1QB rs291982*G allele is a marker of a haplotype carrying "causal" variant located nearby on the first chromosome. In this context it is quite important to note that chromosomal region 1p36 carrying C1QB gene has already been associated with schizophrenia in two genome-wide linkage scans [14,15].

Conclusions

The results obtained suggest that C1QB gene may be considered as a relevant candidate gene for susceptibility to schizophrenia, and its rs291982*G minor allele might represent a risk factor for schizophrenia at least in Armenian population.

Limitations of our study

The first limitation of our study is related to the relatively small sample size of both study groups (225 patients with schizophrenia and 225 healthy subjects), which, however, accounting for total population of Armenia (about 2,800,000) and the incidence of schizophrenia (1%) is nearly optimal for this population. In addition, the statistical power of this study, indicating the difference in the C1QB rs291982*G allele frequency between the patients and healthy controls for the OR = 2.5 reached 100%, for OR = 2.0 99.9%, while for OR = 1.2 was 38.8%. Secondly, we did not reveal how the C1QB rs291982 SNP, significantly associated with schizophrenia in our study, alters the C1QB function. Replication of these data in other centres/populations is required to confirm our results, and also, in the future investigations of functional effects of this genetic variant would be desirable.

Acknowledgements

The authors express their gratitude to the administration and medical staff of the clinics of the Psychiatric Medical Center MH RA and Erebouni Medical Center MH RA, performing diagnostics of the patients, examination of healthy subjects involved in this study, and providing their blood samples for this study. This study was supported by the International Visegrad fund scholarship (RZ: #5091/03830) and the grant (RZ: # ECSP-09-70) of the State Committee of Science of the Ministry of Education and Science of RA and the National Foundation of Science and Advanced Technologies (RA). This work was also supported in part by Palacky University (IGA PU LF 2010_08) and Czech governmental funding (MSM 6198959205).

Author details

1Laboratory of Macromolecular Complexes, Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia, 7 Hasratyan St., 0014, Yerevan, Armenia. 2Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Palacky University, 6 I. P. Pavlova St., 775 20, Olomouc, Czech Republic. 3Nork clinic attached to Psychiatric Medical Center of the Ministry of Health of the Republic of Armenia, 2a G. Hovsepyan St., 0047, Yerevan, Armenia.

Authors’ contributions

RZ performed extraction of DNA and was responsible for genotyping analyses and drafting of the manuscript. AK selected polymorphisms of studied genes, AA performed haplotype analysis. AB generated the main idea of the study. AG was responsible for selection and diagnosis of schizophrenia patients, and the organization of interviews with diseased and healthy subjects. AS designed the primers for selected polymorphisms. MP created study’s laboratory design. Statistical analysis was performed by FM, who together with RZ and MP interpreted the data. AB, FM and MP finalized the manuscript. All authors read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 20 April 2011 Accepted: 28 September 2011 Published: 28 September 2011

References

1. The international statistical classification of diseases and related health problems. 10 edition. World Health Organization, Geneva, 1992, 1243.
2. Diagnostic and statistical manual of mental disorders by the American Psychiatric Association. 4 edition. Amer. Psychiatric Pub., American Psychiatric Association, 2000, 943, text revised.
3. Fatemish SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009, 35(3):528-548.
4. Baron M. Genetics of schizophrenia and the new millennium: progress and pitfalls. Am J Hum Genet 2001, 68(2):299-312.
5. Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV, Mowry C, Laurent BJ, Kendler KS, Nestadt G, Williams NM, Schwab SG, Sanders AR, Nertney D, Mallet J, Worrall B, Lasseter VK, O’Donovan MC, Duan J, Albus M, Alexander M, Godard S, Ribble R, Liang KY, Norton N, Maier W, Papadimitriou G, Walsh D, Jay M, O’Neill A, Lerer FB, Duke RS, Crowe RR, Silverman JM, Levinson DF. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 2009, 14(8):786-795.
6. Boyajyan A, Khoyetsyan A, Chavushyan A. Alternative complement pathway in schizophrenia. Neurochem Res 2010, 35(6):894-898.
7. Boyajyan A, Khoyetsyan A, Tuskanova G, Sim RB. Cryoglobulins as indicators of upregulated immune response in schizophrenia. Clio Biochem 2008, 41(6):355-360.
8. Hakobyan S, Boyajyan A, Sim RB. Classical pathway complement activity in schizophrenia. Neurosci Lett 2005, 374(1):35-37.
9. Mailian KR, Boazdzhian AS, Sopogan AF, Sim RB, Manukian LA. Concentration and protein composition of circulating immune complexes in the blood of patients with schizophrenia and subjects with positive familial history of disease. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova (Moscow) 2005, 105(4):55-60.
10. Mayilyan KR, Arnold JN, Presansis JS, Soghoyan AF, Sim RB. Increased compliment classical and mannann-binding lectin pathway activities in schizophrenia. Neurosci Lett 2006, 404:336-341.
11. Mayilyan KR, Dodds AW, Boyajyan AS, Soghoyan AF, Sim RB. Complement C4B protein in schizophrenia. World J Biol Psychiatry 2008, 9(3):225-230.
12. Maynlink YR, Weinberger DR. Involvement of the HLA genetic diversity in schizophrenia: supporting data and perspectives. *ASH Quarterly* 2008, 32(3):74-77.

13. Maynlink YR, Weinberger DR, Smr RB. The complement system in schizophrenia. *Drug News Perspect* 2008, 21(4):200-210.

14. Xu B, Woodroffe A, Rodriguez-Mutillo L, Roos J, van Rensburg EJ, Abeijan GR, Gogos JA, Karayiorgou M. Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. *Proc Natl Acad Sci USA* 2009, 106(39):16746-16751.

15. Hong KS, Won HH, Cho EY, Jeun HO, Cho SS, Lee YS, Park DJ, Jiang YL, Choi KS, Lee D, Kim MJ, Kim S, Han WS, Kim JW. Genome-wide significant evidence of linkage of schizophrenia to chromosomes 2p24.3 and 6q27 in an SNP-Based analysis of Korean families. *Am J Med Genet B Neuropsychiatr Genet* 2009, 150B(5):647-652.

16. Maes M, Delange J, Janjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. *Psychiatry Res* 1997, 66(1):1-11.

17. Maynlink YR, Weinberger DR. Involvement of the HLA genetic diversity in schizophrenia: supporting data and perspectives. *ASH Quarterly* 2008, 32(3):74-77.

18. Martens HA, Zuurman MW, de Lange AH, Nolte IM, van der Steege G, Martens HA, Zuurman MW, de Lange AH, Nolte IM, van der Steege G, Martens HA, Zuurman MW, de Lange AH, Nolte IM, van der Steege G. Power and replication in case-control studies. *Adv Genet* 2010, 77(23):10262-10631.

19. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured clinical interview for DSM-IV-TR axis I disorders, non-patient edition (SCID-I/NP)*. New York: Biometrics Research, New York State Psychiatric Institute; 2001.

20. Sambrook J, Russell DW. *Molecular Cloning: A Laboratory Manual*. New York: Cold Spring Harbor Laboratory Press; 2001.

21. Bunce M, O'Neil CM, Barnado MC, Krausa P, Browning MJ, Morris PJ, Neil CM, Barnado MC, Krausa P, Browning MJ, Morris PJ. Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity. *Ann Rheum Dis* 2009, 68:715-720.

22. Munoz-Cruz S, Togno-Pierce C, Morales-Montor J. Non-Reproductive Effects of Sex Steroids: Their Immunoregulatory Role. *Curr Top Med Chem* 2011, 11(13):1717-1727.

23. Freier E, Weber CS, Nowottna HC, Huldbrandt T, Cao Y, Pabst C, Muzzulini J, Schnee B, Brunner-Weinzierl MC, Marangozo M, Bokerneyer C, Deter HC, Atanackovic D. Decrease of CD4(+) FOXP3(+) regulatory T cells in the peripheral blood of human subjects undergoing a mental stressor. *Psychoneuroendocrinology* 2010, 35(3):663-673.

24. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. *Mol Biol Evol* 1995, 12:921-927.

25. Lalouel JM, Rohnvasser A. Power and replication in case-control studies. *Am J Hypertens* 2002, 15:201.

26. Rice TK, Shorth NJ, Rao DC. Methods for handling multiple testing. *Adv Genet* 2008, 60:293-308.

27. Farré D, Roset R, Huerta M, Añó LM, Abbà MM, Meseguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. *Nucleic Acids Res* 2003, 31(13):3651-3653.

28. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet* 2002, 3:391-397.

29. Arnosti DN, Kulkarni MM. Transcriptional enhancers: Intelligent enhancers or flexible billboards? *J Cell Biochem* 2005, 94:890-898.

30. Zhang Y, Cheng XR, Zhou WX, Zhang YX. Gene expression patterns of hippocampus and cerebral cortex of senescence-accelerated mouse treated with Huang-Lian-Jie-Du decoction. *Neurosci Lett* 2008, 439(2):119-124.

31. Zakharyan et al. Association of C1Q8 gene polymorphism with schizophrenia in Armenian population. *BMC Medical Genetics* 2011 12:126.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2350/12/126/prepub

doi:10.1186/1471-2350-12-126

Cite this article as: Zakharyan et al.: Association of C1Q8 gene polymorphism with schizophrenia in Armenian population. *BMC Medical Genetics* 2011 12:126.